<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778921</url>
  </required_header>
  <id_info>
    <org_study_id>CSPA100A2304</org_study_id>
    <nct_id>NCT00778921</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone</brief_title>
  <official_title>A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of combination aliskiren/amlodipine in
      patients with hypertension not adequately controlled with amlodipine alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study</measure>
    <time_frame>Baseline and Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker Assessment at Visit 2 (Single Blind Run in), Visit 5 (Randomization), and Visit 9 (EOS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">847</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Amlodipine 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren/Amlodipine 150/10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren/Amlodipine 150/10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren/Amlodipine 300/10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren/Amlodipine 300/10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10 mg</intervention_name>
    <description>Amlodipine 10 mg</description>
    <arm_group_label>Amlodipine 10 mg</arm_group_label>
    <arm_group_label>Aliskiren/Amlodipine 150/10 mg</arm_group_label>
    <arm_group_label>Aliskiren/Amlodipine 300/10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren 150</intervention_name>
    <description>Aliskiren/Amlodipine 150/10 mg</description>
    <arm_group_label>Aliskiren/Amlodipine 150/10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 300</intervention_name>
    <description>Aliskiren/Amlodipine 300/10 mg</description>
    <arm_group_label>Aliskiren/Amlodipine 300/10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed patients or patients who have not been treated for hypertension within
             the 4 weeks prior to Visit 1 must have a msDBP ≥ 95 mmHg and &lt; 110 mmHg at Visits 1
             and 2

          -  Patients who have been treated for hypertension within the 4 weeks prior to Visit 1
             must have a msDBP ≥ 90 mmHg and &lt; 110 mmHg at Visit 2

          -  All patients must have a msDBP ≥ 90 mmHg and &lt; 110 mmHg at Visit 5 (randomization)

        Exclusion Criteria:

          -  Severe hypertension

          -  Pregnant or nursing (lactating) women

          -  Pre-menopausal women not taking accepted form of birth control

          -  Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1

          -  History of cardiovascular conditions

          -  Uncontrolled Type 1 or Type 2 diabetes mellitus

          -  Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with
             similar chemical structures

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>N</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <results_first_submitted>December 13, 2010</results_first_submitted>
  <results_first_submitted_qc>February 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2011</results_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Aliskiren</keyword>
  <keyword>Amlodipine</keyword>
  <keyword>Non-responder to Amlodipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren/Amlodipine 300/10 mg</title>
          <description>Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning</description>
        </group>
        <group group_id="P2">
          <title>Aliskiren/Amlodipine 150/10 mg</title>
          <description>Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning</description>
        </group>
        <group group_id="P3">
          <title>Amlodipine 10 mg</title>
          <description>Oral capsules of amlodipine 10 mg taken once daily with water in the morning</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="279"/>
                <participants group_id="P2" count="285"/>
                <participants group_id="P3" count="283"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="266"/>
                <participants group_id="P3" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Laboratory Value(s)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Test Procedure Result(s)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient No Longer Requires Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew request</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren/Amlodipine 300/10 mg</title>
          <description>Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning</description>
        </group>
        <group group_id="B2">
          <title>Aliskiren/Amlodipine 150/10 mg</title>
          <description>Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning</description>
        </group>
        <group group_id="B3">
          <title>Amlodipine 10 mg</title>
          <description>Oral capsules of amlodipine 10 mg taken once daily with water in the morning</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="279"/>
            <count group_id="B2" value="285"/>
            <count group_id="B3" value="283"/>
            <count group_id="B4" value="847"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="10.19"/>
                    <measurement group_id="B2" value="54.4" spread="10.70"/>
                    <measurement group_id="B3" value="54.3" spread="10.92"/>
                    <measurement group_id="B4" value="54.6" spread="10.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="184"/>
                    <measurement group_id="B4" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study</title>
        <time_frame>Baseline and Week 8</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/Amlodipine 300/10 mg</title>
            <description>Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren/Amlodipine 150/10 mg</title>
            <description>Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Oral capsules of amlodipine 10 mg taken once daily with water in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study</title>
          <population>full analysis set</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="281"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.99" spread="0.462"/>
                    <measurement group_id="O2" value="-8.95" spread="0.460"/>
                    <measurement group_id="O3" value="-7.23" spread="0.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study</title>
        <time_frame>Baseline and Week 8</time_frame>
        <population>full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/Amlodipine 300/10 mg</title>
            <description>Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren/Amlodipine 150/10 mg</title>
            <description>Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Oral capsules of amlodipine 10 mg taken once daily with water in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study</title>
          <population>full analysis set</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="281"/>
                <count group_id="O3" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.42" spread="0.684"/>
                    <measurement group_id="O2" value="-11.01" spread="0.681"/>
                    <measurement group_id="O3" value="-8.20" spread="0.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group</title>
        <time_frame>8 weeks</time_frame>
        <population>Analysis: Intention to Treat (ITT) Imputation Technique: Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren/Amlodipine 300/10 mg</title>
            <description>Oral tablets of combination aliskiren/amlodipine 300/10 mg taken once daily with water in the morning</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren/Amlodipine 150/10 mg</title>
            <description>Oral tablets of combination aliskiren/amlodipine 150/10 mg taken once daily with water in the morning</description>
          </group>
          <group group_id="O3">
            <title>Amlodipine 10 mg</title>
            <description>Oral capsules of amlodipine 10 mg taken once daily with water in the morning</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group</title>
          <population>Analysis: Intention to Treat (ITT) Imputation Technique: Last Observation Carried Forward (LOCF)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="283"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker Assessment at Visit 2 (Single Blind Run in), Visit 5 (Randomization), and Visit 9 (EOS)</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren 300mg/ Amlodipine 10mg</title>
          <description>Aliskiren 300mg/ Amlodipine 10mg</description>
        </group>
        <group group_id="E2">
          <title>Aliskiren 150mg/ Amlodipine 10mg</title>
          <description>Aliskiren 150mg/ Amlodipine 10mg</description>
        </group>
        <group group_id="E3">
          <title>Amlodipine 10mg</title>
          <description>Amlodipine 10mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphoid tissue hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="279"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="281"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

